Introduction: A New Approach to Multi-Receptor Metabolic Therapy
The treatment of metabolic syndrome research has been transformed over the past decade by the emergence of incretin-based therapies — first with single GLP-1 receptor agonists such as GLP-1 agonist peptide and liraglutide, then with the dual GLP-1/GIP receptor agonist GLP dual agonist peptide. These agents have demonstrated that targeting gut-derived hormonal pathways can produce clinically meaningful metabolic regulation research, with the most effective agents achieving 15-24% body metabolic regulation research in clinical trials.[1] The logical scientific question that follows is whether engaging additional metabolic receptors simultaneously could further improve efficacy, broaden the therapeutic profile, or reduce the adverse effects that limit current treatments.
NA-931, also known by the trade name NA-931, represents one answer to that question. Developed by an investigational sponsor, Inc. (San Jose, California), NA-931 is described as a first-in-class oral small-molecule quadruple receptor agonist that simultaneously targets four metabolic hormone receptors: insulin-like growth factor 1 (IGF-1), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.[2] This article provides a comprehensive, evidence-based examination of NA-931's molecular rationale, mechanism of action, clinical trial data, and the current limitations of the available evidence. For context on the broader landscape of research peptides and their scientific applications, see our foundational overview.
Important disclaimer: NA-931 is an investigational compound that has not been approved by the FDA, EMA, or any regulatory agency for any indication. All clinical data discussed in this article are derived from conference presentations and abstracts; no peer-reviewed full-length publications of the trial data were available at the time of writing. Researchers should treat the efficacy and mechanism claims as preliminary pending independent verification.
Molecular Origins: The Cyclic Glycine-Proline Connection
NA-931 is described by its developer as being derived from a cyclic IGF-1 fragment. While the precise molecular structure has not been publicly disclosed, this description aligns with research on cyclic glycine-proline (cGP), a naturally occurring metabolite of IGF-1 that has been studied independently for over two decades. Understanding the cGP pathway provides essential context for evaluating NA-931's claimed mechanism of action.
IGF-1, a 70-amino-acid polypeptide structurally similar to insulin, plays a central role in growth, metabolism, and tissue maintenance. Most circulating IGF-1 is bound to IGF-binding protein 3 (IGFBP-3), which regulates its bioavailability. When free IGF-1 is cleaved at its N-terminus, it produces the tripeptide glycine-proline-glutamate (GPE), which is rapidly metabolized into cGP — a small, cyclic, lipophilic dipeptide that belongs to the diketopiperazine class.[3]
Research published in Scientific Reports demonstrated that cGP retains binding affinity for IGFBP-3 and can compete with IGF-1 for this binding, thereby modulating the amount of bioavailable IGF-1 in circulation. The effect is homeostatic rather than unidirectional: cGP promotes IGF-1 activity when it is insufficient but appears to inhibit it when excessive.[3] Crucially, cGP is orally bioavailable and crosses the blood-brain barrier — properties unusual for peptide-derived compounds and attributable to its small size, cyclic structure, and lipophilicity.[4]
These properties of cGP — oral bioavailability, blood-brain barrier penetrance, IGF-1 pathway modulation, and metabolic stability — are consistent with the pharmacological profile claimed for NA-931, suggesting that the compound may be structurally related to cGP or its analogs. However, in the absence of a disclosed chemical structure or published receptor-binding assays, the exact relationship between NA-931 and the cGP literature remains unconfirmed.
The Quadruple Receptor Mechanism of Action
NA-931's proposed mechanism involves simultaneous engagement of four receptor systems that collectively regulate energy balance, glucose homeostasis, appetite, and body composition. Each pathway contributes a distinct pharmacological dimension to the overall therapeutic effect.
IGF-1 Receptor Pathway
The IGF-1 component distinguishes NA-931 from all other multi-receptor agonists currently in clinical development. Metabolic syndrome research is associated with dysregulated growth hormone/IGF-1 signaling — obese individuals frequently exhibit reduced IGF-1 bioactivity, which correlates with increased adiposity, reduced lean mass, and impaired metabolic function. IGF-1 signaling through the PI3K/Akt pathway is anabolic: it promotes muscle protein synthesis and inhibits proteolysis.[3][4] By restoring IGF-1 pathway activity, NA-931 theoretically addresses one of the most significant limitations of existing weight-loss therapies — the loss of lean muscle mass during caloric deficit. This claim is central to NA-931's differentiation from competitors, though it has not been verified through published body composition data (e.g., DEXA scans) in peer-reviewed literature.
GLP-1 Receptor Pathway
GLP-1 is an incretin hormone released from intestinal L-cells in response to nutrient ingestion. GLP-1 receptor activation produces several well-characterized effects: glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and centrally mediated appetite suppression through hypothalamic and hindbrain circuits. These mechanisms are the foundation of the entire GLP-1 receptor agonist drug class, which includes GLP-1 agonist peptide (/) and liraglutide (Saxenda).[1]
GIP Receptor Pathway
Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone, released from intestinal K-cells. GIP potentiates insulin secretion and may improve adipocyte metabolic flexibility. The combination of GLP-1 and GIP receptor agonism is the basis for GLP dual agonist peptide (/Zepbound), which has demonstrated superior metabolic regulation research compared with GLP-1 monoagonists in head-to-head trials. Importantly, GIP receptor engagement may modulate the emetic signaling associated with GLP-1 receptor activation in the hindbrain, potentially improving gastrointestinal tolerability.[1][5]
Glucagon Receptor Pathway
Glucagon, secreted by pancreatic alpha cells, increases hepatic glucose output, stimulates lipolysis and fatty acid oxidation, reduces appetite, and increases energy expenditure. The inclusion of glucagon receptor agonism in multi-receptor compounds is supported by preclinical data showing that GLP-1/GIP/glucagon triple agonists achieve superior metabolic regulation research compared with dual agonists, primarily through enhanced energy expenditure and hepatic lipid mobilization. The triple agonist GLP triple agonist peptide, which targets GLP-1, GIP, and glucagon receptors, achieved 24.2% metabolic regulation research at 48 weeks in a Phase 2 trial — the highest reported for any metabolic syndrome research pharmacotherapy.[5][6]
NA-931 adds the IGF-1 pathway to this established triple-receptor framework, creating what is described as a quadruple agonist with the combined capacity to suppress appetite (GLP-1, GIP), increase energy expenditure and hepatic fat metabolism (glucagon), improve insulin sensitivity (GLP-1, GIP), and preserve lean mass (IGF-1).[2]
Clinical Trial Data
Phase 1: Safety, Tolerability, and Early Efficacy Signals
The Phase 1 trial (ClinicalTrials.gov ID: NCT06615700) was a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study conducted in otherwise healthy adults who were overweight or obese, with or without type 2 glycemic homeostasis research. A total of 74 subjects received NA-931, with a 28-day treatment period for the multiple-ascending dose cohort.[2][7]
Results were presented at the ADA 85th Scientific Sessions (June 2025, Chicago) and ENDO 2025. The key findings reported by the sponsor include: dose-dependent mean body metabolic regulation researchs from baseline of up to 6.4% (5.1% relative to placebo) after 28 days of treatment; up to 63% of NA-931-treated subjects achieved at least 5% metabolic regulation research, compared with 0% for placebo; treatment-emergent adverse events were reported as insignificant or mild, with 84% of gastrointestinal adverse events classified as insignificant; mild nausea and vomiting were not reported among any NA-931-treated subject; diarrhea was reported in one subject (2.3%) receiving NA-931 versus two subjects (10%) in the placebo group; no muscle loss was observed; and pharmacokinetic data supported a once-daily dosing regimen with consistent blood levels regardless of fasting or fed state.[2][7]
Phase 2: 13-Week Efficacy and Safety
The Phase 2 trial (ClinicalTrials.gov ID: NCT06564753) was a 13-week, randomized, double-blind, placebo-controlled, parallel-arm study that enrolled 125 adults with metabolic syndrome research (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbid condition.[2][8]
Results were presented at ADA 2025, ENDO 2025, and EASD 2025 (Vienna, September 2025). The sponsor reported the following findings: dose-dependent reductions in mean body weight from baseline, with up to 13.8% at the 150 mg daily dosage, representing 12.4% greater metabolic regulation research than placebo (the EASD presentation reported 11.9% relative to placebo); an exploratory analysis showed that up to 72% of NA-931-treated subjects achieved at least 12% metabolic regulation research, compared with 1.9% for placebo; all observed gastrointestinal adverse events were reported as insignificant or mild, with 83% classified as insignificant; mild nausea and vomiting were reported in 7.3% of NA-931-treated subjects; diarrhea was reported in 6.3% of subjects receiving NA-931; no muscle loss was observed; and no clinically meaningful differences in gastrointestinal adverse events were reported between NA-931 and placebo groups.[2][8]
Oral Bioavailability and Pharmacokinetics
A particularly notable feature of NA-931 is its oral route of administration. Most GLP-1 receptor agonists (GLP-1 agonist peptide injection, GLP dual agonist peptide, GLP triple agonist peptide) require subcutaneous injection. The oral formulation of GLP-1 agonist peptide (Rybelsus) requires co-administration with the absorption enhancer SNAC and must be taken on an empty stomach with minimal water. NA-931, by contrast, is reported to maintain consistent pharmacokinetic exposure regardless of food intake, enabling once-daily oral dosing without meal-timing restrictions. The compound is also reported to cross the blood-brain barrier, which may enhance central appetite regulation.[2] These pharmacokinetic properties, if confirmed in peer-reviewed pharmacokinetic studies, would represent meaningful practical advantages for patient adherence.
Comparison with Existing Therapies
Contextualizing NA-931's reported efficacy within the landscape of approved and late-stage metabolic syndrome research pharmacotherapies is essential for understanding its potential significance, while acknowledging the substantial limitations of cross-trial comparisons.
GLP-1 agonist peptide 2.4 mg (), a GLP-1 monoagonist administered by weekly injection, achieved approximately 15% metabolic regulation research at 68 weeks in the STEP trials. GLP dual agonist peptide (Zepbound), a dual GLP-1/GIP agonist administered by weekly injection, achieved 15-21% metabolic regulation research at 72 weeks in the comparative trial trials. GLP triple agonist peptide, a triple GLP-1/GIP/glucagon agonist in development (weekly injection), achieved 24.2% metabolic regulation research at 48 weeks in Phase 2.[1][5]
NA-931's reported 13.8% metabolic regulation research at 13 weeks is notable because the weight-loss trajectory was continuing at study end without a plateau, suggesting that longer treatment could yield substantially greater reductions. The gastrointestinal tolerability profile appears favorable compared with existing agents, where nausea rates typically range from 20-44% for GLP-1 agonist peptide and 12-33% for GLP dual agonist peptide. NA-931's reported 7.3% mild nausea rate, if confirmed, would represent a meaningful improvement in tolerability.[2]
However, these comparisons must be interpreted with extreme caution. The trials differ fundamentally in duration (13 weeks vs. 48-72 weeks), sample size (125 vs. thousands), study populations, dose optimization protocols, and — critically — the NA-931 data have not been published in peer-reviewed form with full methodology, statistical analysis, and independent verification.
Critical Assessment: Limitations of the Current Evidence
Scientific rigor demands a transparent assessment of what remains unknown or unverified about NA-931. Several significant limitations warrant careful consideration by researchers evaluating this compound.
First, the absence of peer-reviewed publications is the most fundamental limitation. As of early 2026, all clinical data come from conference abstracts and sponsor press releases. Full trial reports with detailed methodology, complete adverse event tables, statistical analysis plans, and independent data monitoring committee reports have not been published in peer-reviewed journals. Conference abstracts, while valuable for disseminating preliminary findings, do not undergo the same level of scrutiny as full manuscripts.[2][7][8]
Second, the quadruple receptor agonism claim — particularly the assertion of direct IGF-1 receptor agonism by a small molecule — is biologically unusual and has not been independently verified through published receptor-binding assays or functional pharmacology studies. Direct, selective small-molecule IGF-1 receptor agonism is not established in the broader pharmacological literature. The compound's effects on IGF-1 pathway signaling may be indirect (mediated through IGFBP-3 modulation, as with cGP) rather than through direct receptor binding, and this distinction has significant implications for both mechanism and safety.[3]
Third, the muscle preservation claims lack published body composition data. While no muscle loss was reported, the absence of DEXA or equivalent body composition measurements in published form means this claim has not been substantiated by quantitative imaging data. Fourth, the molecular structure of NA-931 has not been publicly disclosed, preventing independent replication of receptor-binding studies. Fifth, long-term safety data beyond 13 weeks are not available. Given that metabolic syndrome research treatment is inherently chronic, safety signals that emerge over months to years — including potential concerns about glucagon-mediated cardiovascular effects, IGF-1-related mitogenic signaling, gallbladder events, and pancreatobiliary risks — cannot yet be assessed.
Development Status and Future Directions
an investigational sponsor has announced that NA-931 is advancing to Phase 3 clinical trials for metabolic syndrome research and type 2 glycemic homeostasis research. Additional studies are planned or underway: a Phase 2 study (NCT06732245) evaluating the combination of NA-931 with GLP dual agonist peptide in 224 adults with metabolic syndrome research, designed to assess potential synergistic effects; preclinical studies exploring NA-931 for alcohol use disorder, based on data presented showing the compound attenuates alcohol-mediated behavior; and planned studies in metabolic dysfunction-associated steatohepatitis (MASH), leveraging the glucagon receptor's role in hepatic lipid metabolism.[2]
The Phase 3 program will be critical for establishing the compound's place in the therapeutic landscape. Larger sample sizes, longer treatment duration, independent data monitoring, and mandatory peer-reviewed publication of results will provide the evidence base necessary for regulatory evaluation and scientific assessment. For researchers who work with peptides and small molecules in the metabolic space, understanding peptide purity and its impact on research quality remains essential as compounds like NA-931 move through development.
The Multi-Agonist Landscape: Context and Competitors
NA-931 enters a rapidly evolving competitive landscape of multi-receptor metabolic therapies. The progression from monoagonists to dual and triple agonists represents a clear trend in metabolic syndrome research pharmacotherapy, and understanding where NA-931 fits requires appreciation of the broader pipeline.
GLP triple agonist peptide (Eli Lilly), a triple GLP-1/GIP/glucagon agonist, is the most advanced competitor in the multi-agonist space, having demonstrated 24.2% metabolic regulation research in Phase 2 and currently in Phase 3 trials. Survodutide (Boehringer Ingelheim), a dual GLP-1/glucagon agonist, targets metabolic regulation research and MASH. CagriSema (Novo Nordisk) combines GLP-1 agonist peptide with the amylin analog cagrilintide to target complementary appetite pathways. Other metabolic research compounds include AOD-9604, a growth hormone fragment studied for fat metabolism. Orforglipron (Eli Lilly) is an oral, non-peptide GLP-1 receptor agonist that shares NA-931's advantage of oral administration but targets only a single receptor.[1][5]
All of these programs are substantially more advanced in terms of published preclinical pharmacology, clinical data volume, and peer-reviewed validation. NA-931's unique positioning — if its quadruple mechanism is confirmed — lies in the combination of oral delivery with four-receptor engagement and claimed muscle preservation through IGF-1 pathway modulation.
Implications for the Research Community
For researchers working with metabolic peptides and small molecules, NA-931 raises several points of scientific interest. The potential validation of the cGP-IGF-1 axis as a druggable pathway for metabolic syndrome research would represent a significant advance in understanding the intersection of growth factor biology and energy homeostasis. The oral bioavailability of a multi-receptor metabolic agent without absorption enhancers, if confirmed, would address one of the most persistent challenges in peptide and protein drug delivery. The concept of addressing muscle preservation within the weight-loss mechanism itself, rather than as a separate intervention, could reshape how body composition outcomes are evaluated in metabolic syndrome research trials.
At the same time, the limited evidence base demands that researchers maintain appropriate scientific skepticism. Extraordinary mechanistic claims — such as quadruple receptor agonism by a single small molecule including direct IGF-1 receptor engagement — require extraordinary evidence. Until full pharmacological characterization and independent replication are available, NA-931's mechanism should be regarded as a hypothesis supported by early clinical efficacy data rather than an established pharmacological fact.
For researchers interested in the stability and handling considerations relevant to metabolic peptides and small molecules in the research setting, our guides on peptide stability and lyophilized peptide handling provide applicable foundational protocols, though NA-931's specific formulation as an oral capsule represents a different pharmaceutical presentation than typical lyophilized research peptides.
